[Form 4] Twist Bioscience Corp Insider Trading Activity
Rhea-AI Filing Summary
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an automatic sale of 7,205 shares of common stock on February 23, 2026 at an average price of $46.7098 per share. The footnotes state this sale was required to cover tax withholding obligations related to vesting restricted stock units under the company’s equity plans and did not represent a discretionary trade. Following this transaction, she directly owned 863,052 common shares. The filing also lists several employee stock option grants and their vesting terms, which remain outstanding holdings rather than new transactions.
Positive
- None.
Negative
- None.
Insights
Routine CEO tax-withholding sale; signals administrative activity, not thesis change.
The CEO of Twist Bioscience Corp, Emily M. Leproust, reported selling 7,205 common shares at $46.7098 on February 23, 2026. Footnote F1 explains this was a mandated “sell to cover” transaction to satisfy tax withholding on vested restricted stock units.
Because the sale was required under the company’s equity incentive plan and explicitly described as non-discretionary, it functions as an administrative step rather than a voluntary reduction in exposure. After the sale, she still directly held 863,052 shares, so her overall ownership remains substantial.
The filing also details multiple employee stock option awards and vesting schedules, including performance stock options that became exercisable after meeting criteria. These entries describe existing equity incentives and vesting mechanics; they do not reflect new purchases or sales, so their impact depends on future exercises and company performance.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 7,205 | $46.7098 | $337K |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
